Aims CD36 has been shown to associate with non-receptor Src kinases to activate mitogen-activated protein kinases and trigger cytoskeletal remodelling, important events in foam cell formation and macrophage migration. Yet, its role in regulating circulating mononuclear phagocyte trafficking to atherosclerotic lesions has not been investigated. The aim of the present study was to investigate the role of CD36 in modulating the recruitment of mononuclear phagocytes to the arterial wall and the associated vascular inflammation, using both pharmacological and genetic approaches. Methods and results Apolipoprotein E-deficient (apoE 2/2 ) mice fed a high-fat, high-cholesterol diet were treated daily with a CD36 ligand, EP 80317 (300 mg/kg), or 0.9% NaCl for 6 or 12 weeks. Fortyeight hours before sacrifice, mice were injected iv with 111 Indium-labelled macrophages. A 65% (P , 0.001) reduction of labelled macrophage accumulation at aortic lesions was observed in EP 80317-treated mice, mainly at the level of the aortic arch and iliac arteries, correlating with a 43% reduction of atherosclerotic lesion areas. This was associated with reduced phosphorylation of the focal adhesion kinase Pyk2 following stimulation with oxidized phospholipid in a Src kinase-and CD36-dependent manner. At the vascular level, EP 80317 treatment reduced the expression of pro-inflammatory proteins, including NADPH oxidase, inducible nitric oxide synthase, vascular endothelial cell adhesion molecule-1, and CCL2 chemokine. Plasma IL-6 levels were also reduced by 40% (P , 0.05). In contrast, none of these proteins was modulated in EP 80317-treated apoE/CD36 double knockout (apoE 2/2 /CD36 2/2 ) mice. Conclusion Our results support a role for CD36 signalling in the regulation of mononuclear phagocyte trafficking to atherosclerotic-prone sites and in the associated vascular wall inflammation.
Introduction
CD36, a multiligand class B scavenger receptor expressed by monocytes/macrophages, has been shown to be a key player in atherosclerosis development through oxidized LDL (oxLDL) binding and internalization, thereby leading to macrophage-derived foam cell formation and to their accumulation into fatty streaks.
1 CD36 is also a signalling receptor, and oxLDL was shown to promote CD36 association with the non-receptor Src-like protein tyrosine kinase lyn and the mitogen-activated protein (MAP)/ERK kinase kinase 2 (MEKK2) to signal through the MAP kinases JNK1 and JNK2, as important events in foam cell formation. 2 In another setting, microglial cell migration in response to b-amyloid was associated with a CD36-dependent tyrosine phosphorylation of p130Cas, the p130Cas-binding kinase Pyk2, and the cytoskeletal adaptor protein paxillin, coordinating cytoskeletal rearrangement downstream of CD36. 3 Yet, whether CD36 regulates mononuclear phagocyte trafficking to atherosclerotic lesions remains to be investigated. Along this line, a reduced chemotactic response of CD36-deficient macrophages towards the CCL2 chemokine was observed in vitro. 4 Recruitment of circulating monocytes to atheroscleroticprone areas is known to rely on the upregulated expression of endothelial cell adhesion molecules and pro-inflammatory mediators generated by activated monocytes/macrophages, endothelial, and vascular smooth muscle cells within the arterial wall. 5, 6 In addition to locally generated pro-inflammatory mediators, oxLDL has been reported to increase monocyte binding and transendothelial migration, leading to actin polymerization and LFA-1 integrin activation on circulating monocytes 7 and to the upregulation of cell adhesion molecules at intercellular endothelial junctions. 8 Mildly oxLDL-derived phospholipids, such as oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine and its biologically active components, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine and 1-palmytoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine (POVPC), were also shown to increase monocyte binding to human aortic endothelial cells 9 and to stimulate CCL2 and CXCL8, 10 haem oxygenase-1, and early growth response factor-1 biosynthesis in a number of cell types or tissues. 11 In agreement, POVPC has been characterized as a high affinity ligand for CD36. 12, 13 Altogether, these observations point to a potentially important role of oxLDL and phospholipids in regulating mononuclear phagocyte recruitment to the arterial vascular wall through CD36 signalling, cell adhesion molecules upregulation, and cytokine biosynthesis.
In our previous studies, we showed that EP 80317, which binds selectively to CD36 at a site overlapping that of oxLDL, 14 prevented apolipoprotein E (apoE)-deficient mice (apoE 2/2 ) from developing atherosclerotic lesions. 15 Prolonged treatment was associated with hypocholesterolaemia, reduced oxLDL uptake in macrophages along with an upregulation of signalling proteins involved in cholesterol efflux. 15, 16 In the present study, we have addressed the role of CD36 in mononuclear phagocyte recruitment to aortic lesions and vascular wall inflammation in response to oxLDL and oxidized phospholipids, using both genetic and pharmacological approaches.
111 Indium (In)-labelled macrophages, harvested from both apoE 2/2 and apoE/ CD36 double knockout (apoE 2/2 /CD36 2/2 ) mice, were used as tracer cells to assess the role of CD36 on mononuclear phagocyte trafficking, whereas EP 80317 was used as a pharmacological tool to correlate labelled cell accumulation to lesion areas to the anti-atherosclerotic effect of the drug. In addition, we documented the effect of EP 80317 on the expression of selected inflammatory proteins in whole aortae.
Methods
Detailed materials and methods are provided in the Supplementary material online.
Animals
Experimental procedures were approved by the Institutional Animal Ethics Committee, in accordance with the Canadian Council on Animal Care guidelines for use of experimental animals, conforming to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (A5213-01). ApoE 2/2 / CD36 2/2 mice and their littermate controls were backcrossed six times to C57BL/6 mice. Four-week-old male mice were fed a high-fat, high-cholesterol (HFHC) diet (D12108) and treated daily with EP 80317 (300 mg/kg) or vehicle (0.9% NaCl) sc for a period of 6 or 12 weeks prior to sacrifice.
111
Indium peritoneal macrophage labelling and iv injection InCl 3 chelated with 2-mercaptopyridine N-oxide. 17 Labelled cells [specific activity 1.5 Â 10 6 cpm (counts per minute)/10
6 macrophages] were suspended in murine platelet poor plasma and injected iv (7.5 Â 10 6 cells) into the left subclavian vein of recipient mice, which have been treated with EP 80317 or vehicle for 12 weeks. After 48 h, mice were sacrificed by CO 2 asphyxia, the aortae perfused with 10 mL of PBS and excised from the aortic root to the iliac arteries. The mean cpm was determined in blood and aortae after removing the heart and fat tissues to eliminate non-specific radioactive signal. The specific activity of labelled cells was used to express the data in terms of 111 In-labelled cells per aorta, after correcting for 111 In decay and leakage from cells over time, and normalizing to 10 3 circulating labelled cells. The distribution of isotope-labelled cells throughout the aortic tree was visualized by digital autoradiography (Phosphor Imager screen). Lesion areas of each aorta were assessed by digital analysis following oil red-O staining.
Plasma analysis
Inflammatory biomarkers were assessed using a mouse atherosclerosis antibody array I (RayBiotech Inc., Norcross, GA, USA) and plasma IL-6 levels were determined using a mouse ELISA kit (Quantikine w , R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.
Cell culture
RAW 264.7 murine macrophage-like cells or peritoneal macrophages were cultured in DMEM containing 10% FBS. Cells were starved overnight in the presence or absence of 10 27 M EP 80317 or EP 51389, and then incubated with 10 mg/mL POVPC for either 10 (peritoneal macrophages) or 30 min (RAW cells). In some experiments, RAW cells were pre-incubated for 30 min with an anti-CD36 antibody (10 mg/ mL) against rat 164-182 residues or with an isotype matched IgG prior to POVPC stimulation. Additional experiments were performed to assess the effect of 4 mM PP2, a non-selective Src kinase inhibitor, or its inactive analogue, PP3.
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from entire aortae with Trizol, then reversed transcribed with random primers. Products were amplified by PCR, separated by agarose gel electrophoresis, and visualized as detailed in the Supplementary material online.
Western blot
Aortic or cellular proteins were separated on SDS-PAGE gel, transferred to nitrocellulose membranes, and incubated overnight with antibodies against inducible nitric oxide synthase (iNOS), gp91 phox , phospho-Pyk2 (P-Pyk2), Pyk2, or b-actin. The membranes were washed, incubated with horseradish peroxidase-conjugated secondary antibody, and visualized by chemiluminescence (detailed in the Supplementary material online).
Immunostaining
Deparaffinized sections of the aortic arch were incubated overnight with primary antibodies against vascular endothelial cell adhesion molecule-1 (VCAM-1) or CCL2 chemokine. Purified rabbit and goat IgG were used as primary negative control antibodies. Sections were incubated with biotinylated secondary antibodies and staining was revealed as detailed in the Supplementary material online. Positively stained areas for VCAM-1 were quantified and expressed as the percentage of the total perimeter of the endothelial lining of the vessel.
Statistical analysis
Data are expressed as mean + SEM. Statistical comparisons were performed using a one-way analysis of variance followed by pairwise multiple comparisons using the Student-Newman-Keuls test. A value of P , 0.05 was considered significant.
Results

EP 80317 reduced
111 In-labelled-macrophage recruitment to atherosclerotic lesions A prolonged (12 weeks) treatment of HFHC-fed apoE 2/2 mice with EP 80317 reduced 111 In-labelled macrophage accumulation to lesion-prone sites by 65% (P , 0.001), from 16.4 + 2.3 to 5.8 + 2.4 Â 10 3 111 In-macrophages/ aorta ( Figure 1A and B). This was paralleled by a 43% (P , 0.001) reduction in oil red-O staining of neutral lipids in lesion areas ( Figure 1C and D) . In addition, EP 80317 reduced total plasma cholesterol levels by 27% (P , 0.05) (data not shown), in agreement with our previous studies. 15 
EP 80317 reduced POVPC-induced Pyk2 phosphorylation in macrophages
RAW cells expressed CD36 on plasma membrane as detected by FACS analysis (data not shown). POVPC (10 mg/mL) induced maximal phosphorylation of the protein tyrosine kinase Pyk2 in RAW cells after 30 min incubation, as shown by a 2.3-fold increase in the mean P-Pyk2/Pyk2 ratio (P , 0.01) (Figure 2A) . In a similar manner, a 2.4-fold increase in the mean P-Pyk2/Pyk2 ratio (P , 0.01) was observed after 10 min incubation in peritoneal macrophages (data not shown). Overnight pre-incubation with 10 27 M EP 80317 reduced POVPC-elicited Pyk2 phosphorylation, by 40 + 3.5% and 25 + 1.9% (P , 0.01) in RAW cells ( Figure 2B ) and apoE 2/2 peritoneal macrophages ( Figure 2C ), respectively. EP 80317 exerted similar inhibitory effect on oxLDL (25 mg/mL)-stimulated RAW cells (data not shown). In contrast, pre-incubation of RAW cells with 10 27 M EP 51389, a tripeptide GHRP analogue that is devoid of binding affinity to CD36, did not modulate POVPC-induced phosphorylation of Pyk2 in mononuclear cells ( Figure 2B ).
POVPC-induced Pyk2 phosphorylation in macrophages is CD36-and Src-dependent
To further investigate the role of CD36 in POVPC-induced Pyk2 phosphorylation, RAW cells were incubated with an anti-CD36 antibody (10 mg/mL) prior to POVPC stimulation. The anti-CD36 antibody inhibited POVPC-induced Pyk2 phosphorylation by 38% (P , 0.01), further supporting that POVPC-elicited Pyk2 activation is CD36-dependent ( Figure 3A) . A role for Src kinases as proximal signalling proteins leading to Pyk2 phosphorylation in response to POVPC was then investigated. Pre-incubating RAW cells with 4 mM PP2, a non-selective Src kinase inhibitor, greatly reduced Pyk2 phosphorylation below the levels detected in unstimulated cells, suggesting that basal as well as POVPC-induced Pyk2 phosphorylation are regulated by Src kinases. Treatment with the inactive analogue PP3 had no inhibitory effect ( Figure 3B ).
Reduced expression of plasma and vascular inflammatory proteins in EP 80317-treated mice
Aortae from apoE 2/2 mice showed reduced mRNA and protein levels of inflammatory biomarkers, including subunits of the NAD(P)H oxidase, as well as of iNOS, CCL2, and VCAM-1 ( Figure 4) . Indeed, vascular wall mRNA levels of gp91 phox and p40 phox were reduced by 67% (P , 0.001) and 61% (P , 0.05), respectively, and that of iNOS by 57% (P , 0.05), as assessed by RT-PCR analysis ( Figure 4A) . In agreement, protein levels of the catalytic subunit gp91 phox and iNOS were reduced by 50% and 38%, respectively (P , 0.05), as assessed by western blot analysis ( Figure 4C ). In addition, a chronic treatment with EP 80317 reduced the mRNA levels of VCAM-1 and that of the CCL2 chemokine (P , 0.05) ( Figure 4A) by 50%, as well as endothelial VCAM-1 immunostaining in aortic cross-sections ( Figure 4D) . A similar profile was observed for CCL2 ( Figure 4E) . In contrast, the mRNA levels of anti-oxidant enzymes, including SOD-1, catalase, and GPx-1, were not significantly modulated following EP 80317 treatment of apoE 2/2 mice ( Figure 4B) . Furthermore, circulating plasma levels of a number of inflammatory proteins were found lower in EP 80317-treated apoE 2/2 mice than in vehicle-treated mice ( Figure 6A) , as shown by a 40% reduction in IL-6 plasma levels, from 19.1 + 1.6 to 11.5 + 2.2 pg/mL (P , 0.05) ( Figure 6B ). In addition, TNFa, M-CSF, GM-CSF, MIP-3a, RANTES, IL-1a, IL-1b, IL-2, and IL-4 plasma levels also appeared to be reduced in EP 80317-treated apoE 2/2 mice, as assessed in a protein array ( Figure 6A ). 
The effect of EP 80317 is CD36-dependent
EP 80317 did not attenuate the accumulation of labelled mononuclear cells that were deficient in CD36 ( Figure 5A ), nor Pyk2 phosphorylation in these cells ( Figure 5B) . Furthermore, gp91 phox , iNOS, VCAM-1, and CCL2 mRNA levels were not modulated by EP 80317 treatment in aortae of apoE 2/2 / CD36 2/2 mice ( Figure 5C ). In addition, plasma levels of inflammatory cytokines, as revealed in a protein array ( Figure 6C ), were not modulated in EP 80317-treated apoE 2/2 /CD36 2/2 mice. In agreement, basal IL-6 plasma levels, although lower in apoE 2/2 /CD36 2/2 (10.4 + 2.5 pg/mL) mice than in apoE 2/2 mice, were not further modulated by EP 80317 treatment (8.6 + 1.4 pg/mL) ( Figure 6D ).
Discussion
The principal finding of this study is the demonstration of a role for CD36 in the regulation of mononuclear phagocyte trafficking to atherosclerotic lesion areas, leading to reduced vascular wall inflammation. Furthermore, we have identified this process to be linked to the activation of the focal adhesion kinase Pyk2, in a Src kinase-dependent manner. Monocytes/macrophages play a central role in atherogenesis, and their recruitment to the arterial wall is tightly regulated by inflammatory cytokines, monocyte chemoattractants, cell adhesion molecules, [18] [19] [20] [21] oxLDL, and phospholipids, 19, [21] [22] [23] which may act in a concurrent or sequential manner to facilitate the different steps (margination, adhesion, and diapedesis) leading to phagocyte extravasation and their uptake of oxLDL and phospholipids. In the present study, both genetic and pharmacological approaches were used to delineate the role of the receptor scavenger CD36 in mononuclear phagocyte trafficking and vascular inflammation of the aortic tree, in view of its critical role in the pathogenesis of atherosclerosis. 1, 24 To specifically address the role of CD36 in mononuclear phagocyte recruitment, we injected labelled CD36 þ/þ or CD36 2/2 mononuclear phagocytes into apoE-deficient mice recipients which have been treated or not with a selective ligand of CD36, EP 80317, using a drug regimen known to provide potent and prolonged anti-atherosclerotic effect. 15 To this purpose, total peritoneal cells mainly composed of macrophages were collected from unstimulated mice and used without further purification steps to avoid either in vivo or ex vivo cell activation before labelling. 17, [25] [26] [27] Labelled peritoneal macrophages injected iv in mice were previously shown to migrate successfully to inflammatory sites, despite yielding low number of cells in circulation as a consequence of cell trapping in pulmonary capillaries. 28 Labelled macrophages were proposed to be used as a surrogate for the study of monocyte accumulation to inflammatory foci. 29 In agreement, we found that 111 In-labelled macrophages were recruited to atherosclerotic-prone sites, as shown for labelled monocytes. 5 The distribution of the newly recruited labelled cell in the aortic tree, as detected by autoradiography, coincided with neutral lipid staining areas, with predominant staining at the level of the aortic arch and iliac arteries. In previous studies, CD36 expression was shown to be upregulated during monocyte differentiation to macrophage, and following oxLDL stimulation. 30 Hence, exposure of circulating mononuclear phagocytes to oxLDL and other stimuli during atherosclerosis progression in mice may lead to CD36 upregulation in circulating blood monocytes of atherosclerotic mice. A chronic administration of EP 80317 in atherosclerotic mice did not, however, modulate CD36 protein expression in macrophages 15 and is therefore unlikely to account for reduced mononuclear phagocyte cell trafficking. Overall, taking into account the distribution of labelled cells to atherosclerosis-prone areas and the lack of effect of EP 80317 in modulating CD36-deficient cell recruitment, our results strongly support that the tracer cells behaved as expected for circulating monocytes and that CD36 contribute to the regulation of blood mononuclear phagocyte trafficking to atherosclerotic lesions, as shown by a reduction in 111 In-labelled mononuclear phagocyte recruitment to lesion areas in EP-80317-treated mice ( Figure 1B) .
Considering that EP 80317-binding site to CD36 partially overlap that of oxLDL, 14 it may be possible that EP 80317 compete with oxidized lipoproteins 31 and oxidized phospholipids 32 for CD36 binding. However, oxLDL has also been shown to regulate monocyte trafficking indirectly, through upregulating chemokines such as CCL2 within intima and/ or endothelial lining. [33] [34] [35] Alternatively, a crosstalk between CD36 and 7-transmembrane chemokine receptors and/or cell adhesion molecules may regulate mononuclear phagocyte trafficking, as suggested by the reduced CCL2-stimulated chemotaxis of CD36-deficient macrophages. 4 Stuart et al. 3 showed that activation of Pyk2 contributed to the remodelling of actin cytoskeleton and microglia migration following stimulation of CD36 by b-amyloid. In agreement, our results show that CD36 signalling elicited by POVPC leads to Pyk2 phosphorylation, the latter being abrogated by a specific anti-CD36 antibody (Figure 3) . In a similar manner, targeted deletion of CD36 inhibited Pyk2 phosphorylation, as well as tracer cell accumulation to lesions ( Figure 5A and B) , further supporting a role for CD36 signalling in mononuclear phagocyte trafficking. [36] [37] [38] [39] Members of the Src family kinases have previously been shown to initiate signalling downstream of CD36 2, 3, 40 and their activation was recently found to result in a CD36-dependent phosphorylation of FAK, another member of the focal adhesion kinase family. 41 In agreement, activation of Src kinases downstream of CD36 likely contributed to Pyk2 phosphorylation, as shown by the abrogation of POVPC-induced Pyk2 activation by Src kinase inhibitors. Furthermore, EP 51389, a GHRP analogue devoid of binding affinity to CD36 did not modulate Pyk2 phosphorylation ( Figure 2B ), also in line with a role of CD36 signalling in the regulation of Pyk2 phosphorylation.
Owing to the short intracytoplasmic domains of CD36, it has been proposed that CD36 may signal through its interaction with other transmembrane signalling receptors such as b1-and b3-integrins, SRA, and TLR2. [42] [43] [44] [45] [46] Along that line, Bamberger et al. 44 identified a multireceptor complex for b-amyloid stimulation involving CD36, a6b1 integrin, and the integrin-associated protein CD47, which appears to mediate the adhesion of b-amyloid to microglia and subsequent signalling pathways. In recent studies, oxLDL-elicited CD36 signalling in monocytes was shown to occur independently of TLR2 and SRA, with the short carboxy-terminal intracellular domain of CD36 sufficient for the recruitment of the Src kinase lyn and MEKK2 activation, although a crosstalk between CD36 and SRA pathways could not be excluded. 2 In platelets, integrin outside-in signalling appeared not to be involved in oxLDL-induced JNK activation downstream of CD36. 40 Yet, a potential crosstalk between CD36 and b1-or b2-integrins in regulating monocyte trafficking to aortic lesions might be possible.
We also investigated whether the reduced mononuclear phagocytes trafficking to lesion areas could be correlated with reduced systemic and/or vascular inflammation. Our results show that a chronic treatment with EP 80317 in apoE 2/2 mice attenuated total aortic expression of VCAM-1 and CCL2, as well as that of iNOS and NAD(P)H oxidase, at both the mRNA and protein levels ( Figure 4) . Reactive oxygen species, whether generated in activated endothelium, macrophages, or vascular smooth muscle cells, as well as iNOS-derived NO, are key players in atherosclerosis plaque progression. 47, 48 However, the role of NAD(P)H oxidase in atherosclerotic plaque development has been questioned inasmuch as knocking out the catalytic gp91 phox subunit in apoE-deficient mice did not prevent atherosclerosis progression. 49 In contrast, a correlation between gp91 phox mRNA levels and the severity of atherosclerosis has been reported previously. 50 In agreement with the latter, a role for NAD(P)H oxidase in atherosclerosis following the disruption of p47 phox was shown by reducing lesion areas in descending aortae of apoE 2/2 mice. 51, 52 In agreement, our results show that a chronic treatment with EP 80317, as a selective CD36 ligand, reduced both gp91 phox and iNOS mRNA and protein levels in aortae. In the context of atherosclerosis, both monocytes/macrophages and vascular smooth muscle cells (which also express CD36 in contrast to aortic endothelial cells) may be targets of the peptide. Reduced gp91 phox and iNOS may contribute to reduce vascular wall oxidative stress and thereby LDL oxidation, thus breaking the vicious circle of events leading to vascular wall inflammation and monocytes/macrophages accumulation in intima. A link between CD36 and ROS formation has already been proposed in the context of cerebral ischaemia and reperfusion, where the levels of ROS are markedly reduced in CD36-deficient mice following reperfusion. 53 A possible mechanism whereby EP 80317 may exert its anti-atherosclerotic effect may be through the activation of the PPARg-LXRa-ABC transporter pathway in macrophages, 15 which in addition to regulating cholesterol efflux, negatively regulates iNOS expression 54 and pro-inflammatory cytokines including TNF-a, IL-1b, and IL-6 in human monocytes. 55 Hence, the latter may also account for the anti-inflammatory activity of the peptide at the vascular level, as well as for reduced IL-6 plasma concentrations ( Figure 6) . Further studies will be necessary to Figure 6 Effect of EP 80317 on plasma inflammatory cytokines. Cytokine array of plasma pooled from: (A) 10 apoE 2/2 and (C ) 10 apoE 2/2 CD36 2/2 mice per group, pre-treated or not for 12 weeks with EP 80317 (300 mg/kg/day) (detailed design of the protein array is presented in the Supplementary material online). Plasma IL-6 levels, as assessed by high sensitivity ELISA in: (B) apoE 2/2 mice and (D) apoE 2/2 /CD36 2/2 mice. Results are the mean + SEM, n ! 4 mice per group; *P , 0.05. understand the molecular mechanisms underlying the antiinflammatory effect of the peptide, as well as the potential crosstalk between CD36, integrins, and chemoattractant receptor signalling in regulating monocyte trafficking and vascular wall inflammation.
In conclusion, our data show that a systemic treatment with EP 80317 reduces mononuclear phagocyte trafficking to atherosclerotic lesion areas in a CD36-and Src kinasedependent manner, in association with reduced vascular wall inflammation. Targeting CD36 may represent a novel anti-atherosclerotic strategy.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
